Back to top
January
19
2017

Neurocrine misses endpoint in phase 2 Tourette trial

A phase 2 trial of Neurocrine’s Ingrezza in Tourette syndrome has missed its primary endpoint. The vesicular monoamine transporter 2 inhibitor failed to outperform placebo…

Read More
January
13
2017

Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline

Moderna Therapeutics, based in Cambridge, Mass., has raised $1.9 billion at a valuation approaching $5 billion–higher than most publicly traded biotechnology companies. But the company…

Read More
January
9
2017

ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 9, 2017– ARIAD Pharmaceuticals (NASDAQ:ARIA) (“ARIAD”) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company…

Read More
December
16
2016

Valeant Loses Three Key Executives

The ship called Valeant just keeps sinking, and some of its officers do not plan to go down with it. Three key execs, EVPs Ari…

Read More
December
16
2016

Acetylon Pharmaceuticals To Be acquired By Celgene

Acetylon Pharmaceuticals announced that it has entered into an agreement to be acquired by Celgene Corporation. Prior to the consummation of the acquisition, Acetylon will…

Read More
December
13
2016

Akili, Pfizer successfully gamify Alzheimer’s

Back in 2014, Pfizer teamed up with Akili Interactive Labs to see if a video game could really detect early signs of Alzheimer’s. Now, the…

Read More
"Every science begins as philosophy and ends as art." Will Durant,